Head to Head Contrast: Elicio Therapeutics (NASDAQ:ELTX) vs. Zenas BioPharma (NASDAQ:ZBIO)

Zenas BioPharma (NASDAQ:ZBIO) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Zenas BioPharma and Elicio Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1	2	6	0	2.56
Elicio Therapeutics	1	0	2	1	2.75

Zenas BioPharma currently has a consensus price target of $44.29, indicating a potential upside of 148.24%. Elicio Therapeutics has a consensus price target of $18.00, indicating a potential upside of 96.29%. Given Zenas BioPharma’s higher probable upside, analysts clearly believe Zenas BioPharma is more favorable than Elicio Therapeutics.

Risk & Volatility

Zenas BioPharma has a beta of -0.61, indicating that its share price is 161% less volatile than the S&P 500. Comparatively, Elicio Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.

Institutional and Insider Ownership

35.0% of Elicio Therapeutics shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 28.7% of Elicio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Zenas BioPharma and Elicio Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10.00 million	112.62	-$377.74 million	($8.47)	-2.11
Elicio Therapeutics	N/A	N/A	-$39.57 million	($2.40)	-3.82

Elicio Therapeutics has lower revenue, but higher earnings than Zenas BioPharma. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Zenas BioPharma and Elicio Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Elicio Therapeutics	N/A	-2,748.16%	-151.12%

Summary

Elicio Therapeutics beats Zenas BioPharma on 7 of the 13 factors compared between the two stocks.

About Zenas BioPharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.